Spacek Jiri, Ndukwe Munachiso Onyedikachi, Ubom Akaninyene Eseme Bernard, Sirak I, Hoffman Petr, Karasek Dominik, Petera Jiri, Brodak Milos, Balik Michal, Habes Dominik, Pacovsky Jaroslav
Department of Urology, University Hospital Hradec Kralove, Hradec Králové, Czech Republic.
Department of Obstetrics and Gynecology, University Hospital Hradec Kralove, Hradec Králové, Czech Republic.
Cancer Rep (Hoboken). 2025 Apr;8(4):e70134. doi: 10.1002/cnr2.70134.
In developed countries, urologic fistulas arise mainly from malignancies, radiotherapy, or surgical trauma. Hysterectomy and radiation therapy are both critical components of the treatment of women with cancers. Urologic fistulas significantly reduce the quality of life of cancer patients, and may result in delays or even refusal of adjuvant treatment by these patients, thereby negatively impacting both short- and long-term cancer survival.
A 10-year retrospective study of urologic fistulas associated with gynaecologic malignancies at the University hospital Hradec Kralove, Czech Republic was conducted. Descriptive statistics of the fistula and treatment characteristics of women with malignant fistulas were conducted using the NCSS 22 statistical software program (NCSS, Keysville, Utah).
Cervical cancer was mostly commonly associated with urologic fistulas (36, 76.8%). Most of the malignant fistulas were complex (41, 87.2%) vesicovaginal (23, 48.9%) fistulas (VVFs). More than two-thirds (33, 70.2%) of the fistulas were diagnosed following radiotherapy, with a time interval from radiotherapy to fistula diagnosis of between 3.00 and 14.50 years. Primary fistuloraphy was performed for all the six cases with simple VVFs and seven (41.2%) of the 17 patients with complex VVFs. Treatment success rate was 83.33% and 14.3% for simple and complex fistulas, respectively. All the failed complex fistula repairs recurred.
Malignant fistulas predominantly follow radiotherapy for cervical cancers, and are usually detected up to 15 years post-radiotherapy. Most are complex VVFs, which are difficult to treat, with a high rate of recurrence.
在发达国家,泌尿系统瘘主要源于恶性肿瘤、放射治疗或手术创伤。子宫切除术和放射治疗都是癌症女性患者治疗的关键组成部分。泌尿系统瘘会显著降低癌症患者的生活质量,并可能导致这些患者延迟甚至拒绝辅助治疗,从而对癌症患者的短期和长期生存产生负面影响。
对捷克共和国赫拉德茨克拉洛韦大学医院与妇科恶性肿瘤相关的泌尿系统瘘进行了一项为期10年的回顾性研究。使用NCSS 22统计软件程序(NCSS,犹他州凯斯维尔)对瘘管的描述性统计和恶性瘘管女性患者的治疗特征进行了分析。
宫颈癌最常与泌尿系统瘘相关(36例,占76.8%)。大多数恶性瘘管是复杂的(41例,占87.2%)膀胱阴道瘘(23例,占48.9%)(VVF)。超过三分之二(33例,占70.2%)的瘘管是在放射治疗后诊断出来的,从放射治疗到瘘管诊断的时间间隔为3.00至14.50年。对所有6例单纯VVF病例和17例复杂VVF患者中的7例(占41.2%)进行了一期瘘管修补术。单纯瘘管和复杂瘘管的治疗成功率分别为83.33%和14.3%。所有复杂瘘管修补失败的病例均复发。
恶性瘘管主要发生在宫颈癌放射治疗后,通常在放射治疗后15年内被发现。大多数是复杂的VVF,难以治疗,复发率高。